Last Price
0.296
Today's Change
-0.006 (1.98%)
Day's Change
0.295 - 0.307
Trading Volume
822,099
Market Cap
2 Million
Shares Outstanding
7 Million
Avg Volume
1,481,626
Avg Price (50 Days)
1.07
Avg Price (200 Days)
4.20
PE Ratio
0.00
EPS
154.81
Earnings Announcement
12-Aug-2024
Previous Close
0.30
Open
0.31
Day's Range
0.2945 - 0.3068
Year Range
0.294 - 128.0
Trading Volume
872,938
1 Day Change
-2.02%
5 Day Change
-66.02%
1 Month Change
-71.30%
3 Month Change
-46.24%
6 Month Change
-61.10%
Ytd Change
-95.42%
1 Year Change
-99.68%
3 Year Change
-99.99%
5 Year Change
-99.99%
10 Year Change
-99.99%
Max Change
-99.99%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.